keyword
MENU ▼
Read by QxMD icon Read
search

Pitavastatine

keyword
https://www.readbyqxmd.com/read/29107984/treatment-with-proteasome-inhibitor-bortezomib-decreases-organic-anion-transporting-polypeptide-oatp-1b3-mediated-transport-in-a-substrate-dependent-manner
#1
Khondoker Alam, Taleah Farasyn, Alexandra Crowe, Kai Ding, Wei Yue
OATP1B1 and OATP1B3 mediate hepatic uptake of many drugs (e.g., statins) and can mediate transporter-mediated drug-drug-interactions (DDIs). Bortezomib is the first-in-class proteasome inhibitor drug approved by the U. S. Food and Drug Administration for the treatment of multiple myeloma. The potential of bortezomib to cause OATP-mediated DDIs has not been assessed. The current study investigated the involvement of the ubiquitin-proteasome system (UPS) in OATP1B1 and OATP1B3 degradation and determined the effects of proteasome inhibitors on OATP1B1- and OATP1B3-mediated transport...
2017: PloS One
https://www.readbyqxmd.com/read/29089470/pitavastatin-attenuates-ages-induced-mitophagy-via-inhibition-of-ros-generation-in-the-mitochondria-of-cardiomyocytes
#2
Zhimin Zha, Junhong Wang, Shiling Li, Yan Guo
This study aimed to investigate whether pitavastatin protected against injury induced by advanced glycation end products products (AGEs) in neonatal rat cardiomyocytes, and to examine the underlying mechanisms. Cardiomyocytes of neonatal rats were incubated for 48 hours with AGEs (100mg/mL), receptor for advanced glycation end products (RAGE), antibody (1 mg/mL) and pitavastatin (600 ng/mL). The levels of p62 and beclin1 were determined by Western blotting. Mitochondrial membrane potential (DYm) and the generation of reactive oxygen species (ROS) were measured through the JC-1 and DCFH-DA...
November 1, 2017: Journal of Biomedical Research
https://www.readbyqxmd.com/read/29078817/long-term-effects-of-high-dose-pitavastatin-on-diabetogenicity-in-comparison-with-atorvastatin-in-patients-with-metabolic-syndrome-less-dm-study-protocol-for-a-randomized-controlled-trial
#3
Jun-Bean Park, Ji-Hyun Jung, Yeonyee E Yoon, Hack-Lyong Kim, Seung-Pyo Lee, Hyung-Kwan Kim, Yong-Jin Kim, Goo-Yeong Cho, Dae-Won Sohn
BACKGROUND: The diabetogenic action of statins remains a concern, particularly in patients at high risk for diabetes receiving intensive statin therapy. Despite the risk of diabetes with statin use being considered a potential class effect, recent studies have suggested that pitavastatin exerts neutral or favorable effects on diabetogenicity. However, no randomized trial has compared the long-term effects of pitavastatin with those of other statins on glycemic control in populations at high risk for diabetes...
October 27, 2017: Trials
https://www.readbyqxmd.com/read/29067253/evidence-based-review-of-statin-use-in-patients-with-hiv-on-antiretroviral-therapy
#4
REVIEW
Daniel B Chastain, Kayla R Stover, Daniel M Riche
INTRODUCTION: As a result of improved safe and effective therapeutic options for human immunodeficiency virus (HIV), life expectancy of those living with HIV is increasing leading to new challenges (e.g., management of chronic diseases). Some chronic diseases (e.g., cardiovascular disease [CVD]), are up to two times more prevalent in patients with HIV. Statins are a mainstay of therapy for prevention of CVD; but, clinicians should be aware that not all statins are appropriate for use in the HIV population, especially those receiving antiretroviral therapy (ART)...
June 2017: Journal of Clinical & Translational Endocrinology
https://www.readbyqxmd.com/read/29066168/patterns-and-predictors-of-physician-adoption-of-new-cardiovascular-drugs
#5
Timothy S Anderson, Wei-Hsuan Lo-Ciganic, Walid F Gellad, Rouxin Zhang, Haiden A Huskamp, Niteesh K Choudhry, Chung-Chou H Chang, Seth Richards-Shubik, Hasan Guclu, Bobby Jones, Julie M Donohue
BACKGROUND: Little is known about physicians' approaches to adopting new cardiovascular drugs and how adoption varies between drugs of differing novelty. METHODS: Using data on dispensed prescriptions from IMS Health's Xponent™ database, we created a cohort of all primary care physicians (PCPs) and cardiologists in Pennsylvania who regularly prescribed anticoagulants, antihypertensives and statins from 2007 to 2011. We examined prescribing of three new cardiovascular drugs of differing novelty: dabigatran, aliskiren and pitavastatin...
October 21, 2017: Healthcare
https://www.readbyqxmd.com/read/29030460/hmg-coa-reductase-inhibition-delays-dna-repair-and-promotes-senescence-after-tumor-irradiation
#6
Elena V Efimova, Natalia Ricco, Edwardine Labay, Helena J Mauceri, Amy C Flor, Aishwarya Ramamurthy, Harold G Sutton, Ralph R Weichselbaum, Stephen J Kron
Despite significant advances in combinations of radiotherapy and chemotherapy, altered fractionation schedules and image-guided radiotherapy, many cancer patients fail to benefit from radiation. A prevailing hypothesis is that targeting repair of DNA double strand breaks (DSBs) can enhance radiation effects in the tumor and overcome therapeutic resistance without incurring off-target toxicities. Unrepaired DSBs can block cancer cell proliferation, promote cancer cell death and induce cellular senescence. Given the slow progress to date translating novel DSB repair inhibitors as radiosensitizers, we have explored drug repurposing, a proven route to improving speed, costs and success rates of drug development...
October 13, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28962160/effect-of-eicosapentaenoic-acid-and-pitavastatin-on-electrophysiology-and-anticoagulant-gene-expression-in-mice-with-rapid-atrial-pacing
#7
Maoqing Tong, Jiewen Wang, Yunxin Ji, Xiaomin Chen, Jieru Wang, Shuangshuang Wang, Liemin Ruan, Hanbin Cui, Ying Zhou, Qingyu Zhang, Eiichi Watanabe
Atrial remodeling is considered to be any persistent change in atrial structure or function, and is responsible for the development and perpetuation of atrial fibrillation (AF). Oxidative stress and intracellular pH regulation may also be linked to AF; however it remains unclear whether eicosapentaenoic acid (EPA) or statins have beneficial therapeutic effects. The aim of the present study was to investigate the effects of EPA and pitavastatin on the electrophysiology of and gene expressions in mice with rapidly-paced atria...
September 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28952474/-pitavastatin-tolerability-and-advers-effect-profile
#8
Nevrez Koylan
There are many speculations about the safety of statins which are widely used drugs. In contrast, statins are safer than many widely used drugs. Rhabdomyolysis, the most important adverse event is closely related to plasma drug levels which take drug interactions into account. The most important drugs among interacting drugs are fibrates, antiretroviral drugs and macrolid antibiotics, and, pitavastatin seems to be more advantageous than other statins. Similarly, pitavastatin has better myopathy profile when compared to other statins...
April 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28952473/-pitavastatin-and-new-diabetes-development
#9
Şengül Beyaz, Kubilay Ükinç
Managing dyslipidaemia is central to the management of cardiovascular disease. Statins are the cornerstone of cardiovascular prevention for general population, and in patients with type 2 diabetes mellitus. However, statin therapy predisposes to type 2 diabetes, particularly in patients with predisposition to this condition. Some statins have been associated with increases in blood glucose in patients, and others have shown to have neutral effects, varying from one another their glucose or diabetogenic capacity...
April 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28952472/-cardiovascular-prevention-and-pitavastatin
#10
Meral Kayıkçıoğlu
HMG-CoA reductase inhibitors (statins) represent the most effective class of LDL lowering drugs with an overall positive safety and tolerability profile. They have also consistent benefit in terms of reduced cardiovascular (CV) events in both primary and secondary prevention. Pitavastatin is a new member of the statin class. This review provides a current overview of pravastatin's role in CV risk reduction. In brief pitatastatin has pleitrophic effects as the other statins. It has been shown that it reduces plaque atheroma volume in acute coranary settings...
April 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28952471/-efficacy-of-pitavastatin-on-hdl-cholesterol
#11
Lale Tokgözoğlu
Epidemiological studies have shown that low HDL predicts cardiovascular risk just as much as elevated LDL cholesterol levels. However, today we know that HDL functionality is more important than HDL levels. As a group effect, statins increase HDL levels. They are also thought to increase functional HDL. Pitavastatin is a new statin with a different structure, shown to increase HDL levels more than other statins as well as functionality. Studies have shown that plaque regression occurs with pitavastatin. These findings provide the expectation that it will also decrease cardiovascular events...
April 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28952470/-the-efficacy-and-safety-of-pitavastatin
#12
Vedat Sansoy
In short-term, phase III or IV studies in Asian and European patients, pitavastatin 1, 2 and 4 mg once daily reduced LDL-Cholesterol (LDL-C) 34%, 42% and 47%, respectively. Pitavastatin provided sustained LDL-C-lowering efficacy over up to 60 weeks' therapy in extension studies. In comparative studies pitavastatin 4 mg and simvastatin 40 mg reduced LDL-C similarly, reduction in triglycerides and increase in HDL-Cholesterol (HDL-C) was more prominent with pitavastatin. In comparative studies with atorvastatin, pitavastatin 4mg was found to be more effective than 20 mg of atorvastatin, and a little less effective than 40 mg of atorvastatin...
April 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28943437/inhibiting-prenylation-augments-chemotherapy-efficacy-in-renal-cell-carcinoma-through-dual-inhibition-on-mitochondrial-respiration-and-glycolysis
#13
Jiangrong Huang, Xiaoyu Yang, Xiaochun Peng, Wei Huang
Prenylation is a posttranslational lipid modification required for the proper functions of a number of proteins involved in cell regulation. Here, we show that prenylation inhibition is important for renal cell carcinoma (RCC) growth, survival and response to chemotherapy, and its underlying mechanism may be contributed to mitochondrial dysfunction. We first demonstrated that a HMG-CoA reductase inhibitor pitavastatin inhibited mevalonate pathway and thereby prenylation in RCC cells. In addition, pitavastatin is effective in inhibiting growth and inducing apoptosis in a panel of RCC cell lines...
November 18, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28919704/secondary-prevention-of-major-cerebrovascular-events-with-seven-different-statins-a-multi-treatment-meta-analysis
#14
Ping Zhong, Danhong Wu, Xiaofei Ye, Ying Wu, Tuming Li, Shuwen Tong, Xueyuan Liu
BACKGROUND: Statins have been recommended for the use in atherosclerotic cardiovascular diseases, but different statins have distinct pharmacological characteristics. This multi-treatment meta-analysis aimed to evaluate the efficacy of seven statins in the secondary prevention of major cerebrovascular events (CVEs). METHODS AND ANALYSES: The PubMed, Embase, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials were searched to identify studies published between January 1, 2011, and June 30, 2016...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28917689/effect-of-early-pitavastatin-therapy-on-coronary-fibrous-cap-thickness-assessed-by-optical-coherence-tomography-in-patients-with-acute-coronary-syndrome-the-escort-study
#15
Tsuyoshi Nishiguchi, Takashi Kubo, Takashi Tanimoto, Yasushi Ino, Yoshiki Matsuo, Takashi Yamano, Kosei Terada, Hiroki Emori, Yosuke Katayama, Akira Taruya, Yuichi Ozaki, Yasutsugu Shiono, Kunihiro Shimamura, Takeyoshi Kameyama, Hironori Kitabata, Tomoyuki Yamaguchi, Atsushi Tanaka, Takeshi Hozumi, Takashi Akasaka
OBJECTIVES: The aim of the present study was to assess the effect of early statin therapy on fibrous-cap thickness in coronary plaques of patients with acute coronary syndrome (ACS) by using optical coherence tomography. BACKGROUND: Statins can contribute to the stabilization of coronary plaques. METHODS: This is a prospective, randomized, active-controlled, single-center study. Patients with ACS and untreated dyslipidemia were enrolled and randomly allocated (ratio 1:1) to either the early statin group (received pitavastatin 4 mg/day from baseline) or the late statin group (received pitavastatin 4 mg/day from 3 weeks after the baseline)...
September 9, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28881801/a-screen-for-inducers-of-bhlh-activity-identifies-pitavastatin-as-a-regulator-of-p21-rb-phosphorylation-and-e2f-target-gene-expression-in-pancreatic-cancer
#16
Nicholas Villarino, Lia Signaevskaia, Jaco van Niekerk, Rachel Medal, Heejung Kim, Reyhaneh Lahmy, Kathleen Scully, Anthony Pinkerton, Sangwun Kim, Andrew Lowy, Pamela Itkin-Ansari
The average survival for patients with Pancreatic Ductal Adenocarcinoma (PDA) is merely 6 months, underscoring the need for new therapeutic approaches. During PDA progression, pancreatic acinar cells lose activity of the ClassI/II bHLH factors that regulate quiescence. We previously found that promoting transcriptional activity of the Class I bHLH factor E47 in highly aggressive PDA cells induced stable growth arrest in vitro and in vivo. To translate these findings for clinical utility, we developed a high throughput screening platform to identify small molecule inducers of Class I/II bHLH activity...
August 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28867681/effect-of-intensive-and-standard-pitavastatin-treatment-with-or-without-eicosapentaenoic-acid-on-progression-of-coronary-artery-calcification-over-12-months%C3%A3-prospective-multicenter-study
#17
Toru Miyoshi, Kunihisa Kohno, Hirohiko Asonuma, Satoru Sakuragi, Makoto Nakahama, Yusuke Kawai, Tadahisa Uesugi, Takefumi Oka, Mitsuru Munemasa, Natsuki Takahashi, Naoki Mukohara, Seiji Habara, Yasushi Koyama, Kazufumi Nakamura, Hiroshi Ito
BACKGROUND: The effect of lipid-lowering agents on progression of coronary artery calcification (CAC) remains unclear. We evaluated the effects of pitavastatin 2 mg/day (PIT2), pitavastatin 4 mg/day (PIT4), and PIT2 combined with eicosapentaenoic acid (PIT2+EPA) on CAC progression.Methods and Results:This prospective multicenter study in Japan included patients with an Agatston score of 1-999, hypercholesterolemia, and no evidence of cardiovascular disease. Patients were allocated into PIT2, PIT4, or PIT2+EPA groups...
September 1, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28863874/a-randomized-controlled-trial-of-eicosapentaenoic-acid-in-patients-with-coronary-heart-disease-on-statins
#18
Tetsu Watanabe, Kaoru Ando, Hyuma Daidoji, Yoichiro Otaki, Shigeo Sugawara, Motoyuki Matsui, Eiichiro Ikeno, Osamu Hirono, Hiroshi Miyawaki, Yoshinori Yashiro, Satoshi Nishiyama, Takanori Arimoto, Hiroki Takahashi, Tetsuro Shishido, Takehiko Miyashita, Takuya Miyamoto, Isao Kubota
BACKGROUND: There is a residual risk of coronary heart disease (CHD) despite intensive statin therapy for secondary prevention. The aim of this study was to investigate whether coronary plaque regression and stabilization are reinforced by the addition of eicosapentaenoic acid (EPA) to high-dose pitavastatin (PTV). METHODS: We enrolled 193 CHD patients who underwent percutaneous coronary intervention (PCI) in six hospitals. Patients were randomly allocated to the PTV group (PTV 4mg/day, n=96) or PTV/EPA group (PTV 4mg/day and EPA 1800mg/day, n=97), and prospectively followed for 6-8 months...
August 29, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28855433/effects-of-cardiac-rehabilitation-on-high-density-lipoprotein-mediated-cholesterol-efflux-capacity-and-paraoxonase-1-activity-in-patients-with-acute-coronary-syndrome
#19
Fumiaki Furuyama, Shinji Koba, Yuya Yokota, Fumiyoshi Tsunoda, Makoto Shoji, Youichi Kobayashi
AIMS: We evaluated whether exercised-based cardiac rehabilitation (CR) can ameliorate the HDL function, i.e., cholesterol efflux capacity (CEC) and paraoxonase-1 activity in patients with acute coronary syndrome (ACS). METHODS: This study is a retrospective analysis of stored serum from patients with ACS following successful percutaneous coronary intervention. The CEC, measured by a cell-based ex vivo assay using apolipoprotein B-depleted serum and (3)H-cholesterol labeled macrophages and arylesterase activity (AREA) at the onset or early phase of ACS, and the follow-up periods were compared between 69 patients who completed the five-month outpatient CR program (CR group) and 15 patients who did not participate and/or dropped out from CR program (non-CR group)...
August 30, 2017: Journal of Atherosclerosis and Thrombosis
https://www.readbyqxmd.com/read/28808351/inhibition-of-the-mevalonate-pathway-augments-the-activity-of-pitavastatin-against-ovarian-cancer-cells
#20
Marwan Ibrahim Abdullah, Mohammed Najim Abed, Alan Richardson
Only 40% of patients with advanced ovarian cancer survive more than 5 years. We have previously shown that pitavastatin induces regression of ovarian cancer xenografts in mice. To evaluate whether the response of ovarian cancer cells to pitavastatin is potentiated by farnesyl diphosphate synthase inhibitors or geranylgeraniol transferase I inhibitors, we evaluated combinations of pitavastatin with zoledronic acid, risedronate and GGTI-2133 in a panel of ovarian cancer cells. Pitavastatin (IC50 = 0.6-14 μM), zoledronic acid (IC50 = 21-57 μM), risedronate (IC50 > 100 μM) or GGTI-2133 (IC50 > 25 μM) inhibited the growth of ovarian cancer cell cultures...
August 14, 2017: Scientific Reports
keyword
keyword
3955
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"